About this tool
This tool checks whether an adolescent (12 years or older and 40 kg or more) or adult with COVID-19 can be treated with nirmatrelvir-ritonavir (Paxlovid), and what to do if not. It follows the FDA Emergency Use Authorization fact sheet for healthcare providers (revised February 2026), which covers 12–17 year olds; the drug is FDA-approved for adults.
Answer one step at a time: age and weight, how ill the patient is, days since the first symptom, whether there is a high-risk condition, kidney function (eGFR), severe liver disease, and the most serious interacting medicine the patient takes. The plan appears as soon as the answers decide it, so a patient outside the 5-day window or without a risk factor gets an answer straight away.
When it can be used, the result shows the label regimen for the eGFR (300/100 mg twice daily; 150/100 mg twice daily for eGFR 30 to under 60; 300/100 mg once on day 1 then 150/100 mg once daily for eGFR under 30 or dialysis), how to take it, how to manage the interaction, and the EUA reporting duty for under-18s. When it cannot be used, it gives the reason and the alternative (remdesivir). Sources: FDA EUA fact sheet 02/2026; IDSA 2025 guideline update (adults); NIH pediatric guidance (archived 2024); CDC list of higher-risk conditions.
Common questions
Can a 12-year-old get Paxlovid?
Yes, if they weigh 40 kg or more, have mild to moderate COVID-19 that started 5 days ago or less, and are at high risk of severe disease. It is given under an FDA Emergency Use Authorization at the adult dose. It is not authorized under 12 years or under 40 kg.
What is the Paxlovid dose for kidney disease?
eGFR 60 or more: 300 mg nirmatrelvir with 100 mg ritonavir twice daily for 5 days. eGFR 30 to under 60: 150 mg with 100 mg twice daily. eGFR under 30, including dialysis: 300 mg with 100 mg once on day 1, then 150 mg with 100 mg once daily on days 2–5, given after dialysis on dialysis days (FDA fact sheet, revised 02/2026).
Which drugs cannot be taken with Paxlovid?
Drugs that depend on CYP3A and are dangerous at high levels (for example amiodarone, flecainide, pimozide, lurasidone, oral midazolam, simvastatin, ergotamines, sildenafil for pulmonary hypertension) and strong CYP3A inducers (carbamazepine, phenytoin, phenobarbital, rifampin, St John's wort). Many others need a dose change or monitoring, such as tacrolimus, fluticasone, salmeterol and ethinyl estradiol contraceptives.
Can Paxlovid be started more than 5 days after symptoms began?
No. Treatment should start as soon as possible after the diagnosis and within 5 days of the first symptom. For a high-risk patient between 5 and 7 days, remdesivir by infusion for 3 days is the usual alternative.